Is BMY a Buy or a Sell? The Bull and Bear Case (2026)
Last updated October 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for Bristol Myers Squibb (BMY) rests on New product portfolio ramp: Bristol Myers is shifting revenue weight toward a newer set of growth drivers including Reblozyl, Opdualag, Camzyos, Breyanzi, Sotyktu, and Cobenfy. The bear case rests on the central risk is the patent cliff: Eliquis, Opdivo, and other large products face loss of exclusivity, and generic or biosimilar competition can erode revenue quickly. Analysts covering it publish targets from $41.00 to $82.00 against a $59.75 price, so even the professionals disagree by 62% of their own average. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
Bristol Myers Squibb is one of the largest global biopharmaceutical companies, developing and selling prescription medicines across oncology, hematology, immunology, cardiovascular, and neuroscience. It makes money primarily by selling patented branded drugs, with a portfolio that has historically leaned on blockbuster franchises such as the blood thinner Eliquis (co-marketed with Pfizer), the cancer immunotherapy Opdivo, and the multiple myeloma drug Revlimid. The company is working through a major patent cliff as several legacy products lose exclusivity, and it is rebuilding growth through a newer portfolio that includes drugs like Reblozyl, Opdualag, Camzyos, Sotyktu, and the schizophrenia treatment Cobenfy (acquired through Karuna). Bristol Myers grows both organically through its research pipeline and through large acquisitions (Celgene, MyoKardia, Karuna, Mirati). It is headquartered in New York and operates worldwide. Recent results have run ahead of expectations. Bristol Myers has beaten consensus earnings estimates in each of the last four reported quarters, and Q2 2026 revenue rose about 5.7% year over year to roughly $12.97 billion while adjusted EPS of $2.04 came in well above the $1.60 consensus. Trailing twelve-month revenue is about $49.2 billion and net income about $9.3 billion, a sharp recovery from the acquisition-driven loss of 2024. In October 2026 the company reported Phase 3 results for admilparant, an oral LPA1 antagonist for idiopathic pulmonary fibrosis: in the ALOFT-IPF study the 60 mg dose met its primary endpoint while the 120 mg dose missed statistical significance, a mixed readout that sent the shares lower even as UBS kept a Buy rating and argued the drug remains viable. As of October 16, 2026 BMY closed near $60.80, for a market cap near $124 billion, up about 14% year to date and 40% over one year, though roughly flat over three months and below a 52-week high near $68.64. The stock trades near 13 times trailing and 9 times forward earnings, with a dividend of $2.52 per share a year. Q3 2026 results are scheduled for October 29, 2026, with consensus at about $1.34 adjusted EPS on roughly $12.7 billion of revenue.
The bull case: what would have to be true for $82.00
The most optimistic published target on BMY is $82.00, +37.2% from the $59.75 price as of October 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
1. New product portfolio ramp.
Bristol Myers is shifting revenue weight toward a newer set of growth drivers including Reblozyl, Opdualag, Camzyos, Breyanzi, Sotyktu, and Cobenfy. Management frames these as the engine meant to offset legacy patent losses. The success of this transition, especially Cobenfy in neuropsychiatry, is central to the multi-year growth story and to whether the company can return to durable top-line expansion. Q2 2026 revenue growth of about 5.7% suggests the newer products are carrying more of the load, though consensus still expects 2027 revenue to dip slightly, to about $48.5 billion from about $49.9 billion in 2026.
2. Oncology and immunology depth.
The company has a deep oncology franchise anchored by Opdivo plus cell therapies (Breyanzi, Abecma) and a broad immunology effort led by the oral psoriasis drug Sotyktu. Expanding indications, subcutaneous formulations (Opdivo Qvantig), and combination regimens can extend the life and reach of these franchises, supporting revenue even as older products fade. October 2026 coverage also pointed to a positive late-stage readout in a rare cancer alongside the lung-disease data.
3. Pipeline and disciplined dealmaking.
Bristol Myers has a history of large, focused acquisitions (Celgene, MyoKardia, Karuna, Mirati, RayzeBio) to add pipeline assets and new modalities such as radiopharmaceuticals. A productive late-stage pipeline plus targeted business development is how the company aims to replenish revenue and address the looming exclusivity losses on its biggest legacy products. Admilparant shows both sides of that bet: the 60 mg dose succeeded in idiopathic pulmonary fibrosis, the higher dose did not, and the next questions are how regulators read a split result and whether the drug reaches the larger progressive pulmonary fibrosis market.
4. Strong cash generation.
The branded pharma model produces substantial cash, with about $12.8 billion of operating cash flow and about $8.1 billion of free cash flow over the trailing twelve months on Yahoo's figures. That funds a dividend of $2.52 per share a year (a payout near 55% of trailing earnings), share repurchases, debt reduction after acquisitions, and continued research spending. This cash engine gives management flexibility to manage the patent cliff while still investing in the next generation of medicines.
The bear case: what would have to be true for $41.00
The most pessimistic published target is $41.00, -31.4% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks Bristol Myers Squibb is worth if the risks below bite instead of the drivers above.
The central risk is the patent cliff: Eliquis, Opdivo, and other large products face loss of exclusivity, and generic or biosimilar competition can erode revenue quickly. Revlimid has already declined under generic entry. The newer portfolio must scale fast enough to offset these losses, which is not guaranteed, and consensus already pencils in flat to lower revenue and EPS in 2027. Drug pricing pressure (including US Medicare negotiation under the Inflation Reduction Act, which named Eliquis), clinical trial failures, regulatory setbacks, and integration risk from large acquisitions all weigh on the outlook; the split admilparant readout in October 2026, which also came with protocol changes and a patient death the company said was likely unrelated, is a reminder of how quickly pipeline news can move the stock. Debt of about $45 billion against about $11 billion of cash, and litigation exposure, add further uncertainty.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding BMY already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on BMY
24 analysts cover BMY, with an average target of $65.62 (+9.8% against $59.75) and a split of 10 buy, 17 hold, 1 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the BMY forecast and price target page.
How is BMY valued? (as of October 2026)
Snapshot for BMY as of October 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$49.2 billion (Q2 2026 up ~5.7% YoY)
- Q2 2026 adjusted EPS: $2.04 vs $1.60 consensus
- Operating margin: ~34%
- Net income (TTM): ~$9.3 billion
- P/E trailing / forward: ~13x / ~9x
- Dividend yield: ~4.2% ($2.52/share)
- Free cash flow (TTM): ~$8.1 billion
- Market cap: ~$124 billion
At about $60.80 on October 16, 2026, Bristol Myers trades near 9 times forward earnings, still low relative to large-cap pharma peers, which reflects market skepticism about replacing patent-cliff revenue even after a 40% one-year rally. The 4.2% dividend yield and strong cash flow are the bull-case anchors, while consensus for roughly flat 2027 EPS (about $6.62 versus $6.65 for 2026) captures the bear case. The 24 analysts in Yahoo's consensus carry a mean target near $66, and Q3 2026 results arrive on October 29.
How do you decide if BMY is a buy?
Rather than asking whether BMY is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold BMY indirectly through an index or sector ETF before adding more.
What would change your mind on BMY
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: New product portfolio ramp stalls in the reported numbers rather than in the narrative around them.
- Bear case breaks if: the central risk is the patent cliff: Eliquis, Opdivo, and other large products face loss of exclusivity, and generic or biosimilar competition can erode revenue quickly fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the BMY stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about BMY against your real portfolio and see your actual exposure before deciding.
Investing in Bristol Myers Squibb with AI
Connect the broker you already use and ask Walnut's AI how BMY fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
Is BMY a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on New product portfolio ramp, with revenue (ttm) at ~$49.2 billion (Q2 2026 up ~5.7% YoY). The bear case rests on the central risk is the patent cliff: Eliquis, Opdivo, and other large products face loss of exclusivity, and generic or biosimilar competition can erode revenue quickly. Analysts covering it are spread from $41.00 to $82.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.
Should I sell BMY?
+
Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The central risk is the patent cliff: Eliquis, Opdivo, and other large products face loss of exclusivity, and generic or biosimilar competition can erode revenue quickly. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $41.00, -31.4% from the $59.75 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.
What is the bull case for BMY?
+
New product portfolio ramp. Bristol Myers is shifting revenue weight toward a newer set of growth drivers including Reblozyl, Opdualag, Camzyos, Breyanzi, Sotyktu, and Cobenfy. The most optimistic analyst target on BMY is $82.00, +37.2% from the $59.75 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for BMY?
+
The central risk is the patent cliff: Eliquis, Opdivo, and other large products face loss of exclusivity, and generic or biosimilar competition can erode revenue quickly. Revlimid has already declined under generic entry. The newer portfolio must scale fast enough to offset these losses, which is not guaranteed, and consensus already pencils in flat to lower revenue and EPS in 2027. Drug pricing pressure (including US Medicare negotiation under the Inflation Reduction Act, which named Eliquis), clinical trial failures, regulatory setbacks, and integration risk from large acquisitions all weigh on the outlook; the split admilparant readout in October 2026, which also came with protocol changes and a patient death the company said was likely unrelated, is a reminder of how quickly pipeline news can move the stock. Debt of about $45 billion against about $11 billion of cash, and litigation exposure, add further uncertainty. The most pessimistic published target is $41.00, -31.4% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.
What does Bristol Myers Squibb do?
+
Large biopharma with oncology and immunology drugs, a high dividend, and a patent-cliff turnaround story.
What would have to change for BMY to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (New product portfolio ramp) stalling in the reported numbers rather than in the narrative, the risk above (the central risk is the patent cliff: Eliquis, Opdivo, and other large products face loss of exclusivity, and generic or biosimilar competition can erode revenue quickly) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What is BMY's ticker symbol?
+
BMY, listed on the New York Stock Exchange. The company is Bristol Myers Squibb, headquartered in New York City. It trades during US market hours and is available at every major US brokerage.
What does Bristol Myers Squibb do?
+
Bristol Myers Squibb develops, manufactures, and sells branded prescription medicines across oncology, hematology, immunology, cardiovascular, and neuroscience. Key products include Eliquis, Opdivo, Sotyktu, Camzyos, and Cobenfy. It makes money selling patented drugs globally and grows through its pipeline and acquisitions.
Walnut is informational, not investment advice, and gives no verdict on BMY. Analyst targets referenced here come from a October 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.
Guides that feature BMY
BMY is one of the names covered in these guides. Each one puts the stock next to its peers so you can see where it fits rather than judging it alone.